Evidence map›Paper›PMID 41183192›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics.

Michelle H Teplensky, Julianna N Bourgeois, Sergej Kudruk, Sarah Hurst Petrosko, Chad A Mirkin

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Metal-Phenolic Coatings Enable Universal Design of Spherical Nucleic Acids.Angewandte Chemie (International ed. in English) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michelle H TeplenskyDepartment of Biomedical Engineering, Boston University, Boston, MA 02215.ORCID 0000-0003-4664-420X
Julianna N BourgeoisInterdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, IL 60208.ORCID 0000-0003-2454-2579
Sergej KudrukInternational Institute for Nanotechnology, Northwestern University, Evanston, IL 60208.ORCID 0000-0002-6402-0292
Sarah Hurst PetroskoInternational Institute for Nanotechnology, Northwestern University, Evanston, IL 60208.
Chad A MirkinInterdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, IL 60208.ORCID 0000-0002-6634-7627

Funding

Resource Development CoreU54DK137516 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Evan Alexander Scott · 2023 to 2026
$4.8M
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic AcidsR01CA257926 · NCI · NORTHWESTERN UNIVERSITY · PI CHAD A. MIRKIN, Bin Zhang · 2022 to 2026
$2.5M
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.R01CA275430 · NCI · WASHINGTON UNIVERSITY · PI MIRKIN, CHAD A., STEGH, ALEXANDER H. · 2022 to 2025
$2.3M
Systemic RNA interference to reactivate p53 tumor suppressionR01CA208783 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MIRKIN, CHAD A., STEGH, ALEXANDER H. · 2017 to 2021
$1.8M
Cancer Nanotechnology Training ProgramT32CA186897 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLOSCHAK, GAYLE E. · 2015 to 2019
$1.2M
HHS | NIH | National Cancer Institute (NCI) R01CA275430 R01CA257926 R01CA208783HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U54DK137516NCI NIH HHS R01 CA208783NCI NIH HHS R01 CA257926NCI NIH HHS R01 CA275430NCI NIH HHS T32 CA186897NIDDK NIH HHS U54 DK137516
6 · The paper itself

Abstract

Structural immunotherapy relies on the structural features of immunotherapeutics in addition to component identity to influence biodistribution, intra- or extracellular localization, target engagement, and processing kinetics. This strategy is poised to redefine how immunotherapeutics mobilize immunity against disease and transform our ability to harness structure-function relationships to enhance clinical outcomes.

Indexed as

Drug DesignImmunotherapyAnimalsHumansStructure-Activity Relationshipimmunotherapynanotechnologystructural medicine

Identifiers

PMID41183192
PMCPMC12625970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.